JP2010508855A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010508855A5 JP2010508855A5 JP2009536481A JP2009536481A JP2010508855A5 JP 2010508855 A5 JP2010508855 A5 JP 2010508855A5 JP 2009536481 A JP2009536481 A JP 2009536481A JP 2009536481 A JP2009536481 A JP 2009536481A JP 2010508855 A5 JP2010508855 A5 JP 2010508855A5
- Authority
- JP
- Japan
- Prior art keywords
- erg
- spink1
- expression level
- detected
- detection reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000014509 gene expression Effects 0.000 claims description 93
- 102000001626 Kazal Pancreatic Trypsin Inhibitor Human genes 0.000 claims description 81
- 108010093811 Kazal Pancreatic Trypsin Inhibitor Proteins 0.000 claims description 81
- 230000002018 overexpression Effects 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 52
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 claims description 43
- 239000002299 complementary DNA Substances 0.000 claims description 43
- 210000005267 prostate cell Anatomy 0.000 claims description 38
- 108091034117 Oligonucleotide Proteins 0.000 claims description 37
- 102100021184 Golgi membrane protein 1 Human genes 0.000 claims description 35
- 101001040742 Homo sapiens Golgi membrane protein 1 Proteins 0.000 claims description 35
- 230000003321 amplification Effects 0.000 claims description 34
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 34
- 108091033411 PCA3 Proteins 0.000 claims description 33
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 claims description 33
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 30
- 239000000523 sample Substances 0.000 claims description 27
- 102100039563 ETS translocation variant 1 Human genes 0.000 claims description 24
- 101000813729 Homo sapiens ETS translocation variant 1 Proteins 0.000 claims description 24
- 206010060862 Prostate cancer Diseases 0.000 claims description 20
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 20
- 230000028327 secretion Effects 0.000 claims description 20
- 108091092236 Chimeric RNA Proteins 0.000 claims description 18
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 15
- 239000002751 oligonucleotide probe Substances 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 12
- 101150029838 ERG gene Proteins 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 230000004927 fusion Effects 0.000 claims description 7
- 210000002307 prostate Anatomy 0.000 claims description 7
- 210000002700 urine Anatomy 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 210000000582 semen Anatomy 0.000 claims description 5
- 238000011472 radical prostatectomy Methods 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102100029983 Transcriptional regulator ERG Human genes 0.000 claims 51
- 239000003153 chemical reaction reagent Substances 0.000 claims 46
- 238000001514 detection method Methods 0.000 claims 45
- 239000013610 patient sample Substances 0.000 claims 30
- 108010078184 Trefoil Factor-3 Proteins 0.000 claims 16
- 102100039145 Trefoil factor 3 Human genes 0.000 claims 16
- 239000012472 biological sample Substances 0.000 claims 15
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 claims 12
- 101100203797 Mus musculus Spinkl gene Proteins 0.000 claims 10
- 230000001613 neoplastic effect Effects 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 4
- 230000000977 initiatory effect Effects 0.000 claims 3
- 101150025421 ETS gene Proteins 0.000 claims 2
- 101150015184 Etv1 gene Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 108091071901 ETS family Proteins 0.000 claims 1
- 208000022914 Testicular regression syndrome Diseases 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85775806P | 2006-11-08 | 2006-11-08 | |
| US90687607P | 2007-03-14 | 2007-03-14 | |
| PCT/US2007/084090 WO2008058239A2 (en) | 2006-11-08 | 2007-11-08 | Spink1 as a prostate cancer marker and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013218134A Division JP5850898B2 (ja) | 2006-11-08 | 2013-10-21 | 前立腺癌マーカーとしてのｓｐｉｎｋ１およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010508855A JP2010508855A (ja) | 2010-03-25 |
| JP2010508855A5 true JP2010508855A5 (enExample) | 2011-01-27 |
Family
ID=39365376
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009536481A Pending JP2010508855A (ja) | 2006-11-08 | 2007-11-08 | 前立腺癌マーカーとしてのｓｐｉｎｋ１およびその使用 |
| JP2013218134A Expired - Fee Related JP5850898B2 (ja) | 2006-11-08 | 2013-10-21 | 前立腺癌マーカーとしてのｓｐｉｎｋ１およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013218134A Expired - Fee Related JP5850898B2 (ja) | 2006-11-08 | 2013-10-21 | 前立腺癌マーカーとしてのｓｐｉｎｋ１およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20100129804A1 (enExample) |
| EP (1) | EP2079851B1 (enExample) |
| JP (2) | JP2010508855A (enExample) |
| CN (2) | CN101652484B (enExample) |
| AU (1) | AU2007317306B2 (enExample) |
| CA (1) | CA2668961A1 (enExample) |
| IL (2) | IL198526A (enExample) |
| WO (1) | WO2008058239A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011102999A2 (en) * | 2010-02-19 | 2011-08-25 | The Regents Of The University Of Michigan | Spink1 targeted therapy |
| CA2795242C (en) * | 2010-04-02 | 2019-08-13 | Veridex, Llc | Gene-based prediction of psa recurrence for clinically localized prostate cancer patients |
| WO2012078752A2 (en) * | 2010-12-09 | 2012-06-14 | Philadelphia Health & Education Corporation D/B/A | Serine protease inhibitor kazal antibodies |
| EP3348652B1 (en) * | 2011-05-12 | 2023-07-26 | MDxHealth Research B.V. | Molecular markers in prostate cancer |
| EP2748335B1 (en) * | 2011-08-22 | 2018-10-03 | Exosome Diagnostics, Inc. | Urine biomarkers |
| WO2013036755A1 (en) * | 2011-09-09 | 2013-03-14 | Sloan-Kettering Institute For Cancer Research | Etv1 antibodies and uses thereof |
| EP2786151B1 (en) * | 2011-11-29 | 2019-07-03 | F.Hoffmann-La Roche Ag | Methods for prostate cancer analysis |
| CN103436594A (zh) * | 2012-10-16 | 2013-12-11 | 科蒂亚(新乡)生物技术有限公司 | 一种bdna在尿液中检测pca3的应用 |
| CN102968558B (zh) * | 2012-11-14 | 2015-11-18 | 叶定伟 | 一种预测初诊前列腺癌骨转移风险的装置 |
| WO2016087430A1 (en) * | 2014-12-01 | 2016-06-09 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Novel RNA-biomarker signature for diagnosis of prostate cancer |
| CN104531878B (zh) * | 2015-01-04 | 2017-11-10 | 上海市同济医院 | 一种联合lncRNA和AR3检测试剂盒及应用 |
| CN105717082A (zh) * | 2016-02-02 | 2016-06-29 | 管晓翔 | 一种用于检测三阴性乳腺癌瘤内异质性的方法 |
| KR101948385B1 (ko) * | 2016-09-01 | 2019-05-13 | 충북대학교 산학협력단 | 전립선암 예후 분석용 신규 바이오마커 및 그의 용도 |
| CN109521457B (zh) * | 2018-09-25 | 2022-10-21 | 中国辐射防护研究院 | 一种基于信息准则的γ辐射源项划分方法及系统 |
| CN111110849B (zh) * | 2018-10-11 | 2021-09-10 | 中国科学院上海营养与健康研究所 | 丝氨酸蛋白酶抑制因子Kazal 1型在制备细胞衰老及肿瘤诊断或调控制剂中的应用 |
| CN109678950B (zh) * | 2019-01-08 | 2022-05-10 | 灏灵赛奥（天津）生物科技有限公司 | spink1抗原、能够特异性结合spink1的抗体及其功能片段及其应用和产品 |
| CN109776679B (zh) * | 2019-01-08 | 2022-06-17 | 灏灵赛奥（天津）生物科技有限公司 | 一种丝氨酸蛋白酶抑制因子spink1的抗体、其制备方法和应用 |
| US11788091B2 (en) | 2019-08-21 | 2023-10-17 | University Of Virginia Patent Foundation | Methods and compositions for diagnosing and treating prostate cancer based on long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth |
| US12319967B2 (en) | 2019-08-21 | 2025-06-03 | University Of Virginia Patent Foundation | Methods and compositions for diagnosing and treating prostate cancer based on long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth |
| CN111308095A (zh) * | 2020-03-04 | 2020-06-19 | 北京师范大学 | 用于诊断前列腺癌的尿液蛋白标记物 |
| EP4232605A4 (en) * | 2020-11-11 | 2024-09-25 | University of Virginia Patent Foundation | METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING PROSTATE CANCER BASED ON LONG NON-CODING RNA OVERLAPPING THE LCK GENE REGULATING PROSTATE CANCER CELL GROWTH |
| JPWO2023276768A1 (enExample) * | 2021-06-29 | 2023-01-05 | ||
| CN115181801A (zh) * | 2022-07-11 | 2022-10-14 | 中山大学附属第一医院 | Bhlhe22在前列腺癌骨转移免疫治疗中的应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4323546A (en) * | 1978-05-22 | 1982-04-06 | Nuc Med Inc. | Method and composition for cancer detection in humans |
| JP3448090B2 (ja) * | 1994-02-16 | 2003-09-16 | 浜松ホトニクス株式会社 | エネルギー移動検出法およびその装置 |
| US20050214309A1 (en) * | 1994-03-18 | 2005-09-29 | Hinrichs Steven H | Methods and compositions for modulating transcription factor activity |
| US5854206A (en) * | 1995-08-25 | 1998-12-29 | Corixa Corporation | Compounds and methods for treatment and diagnosis of prostate cancer |
| EP0914335A2 (en) * | 1996-03-15 | 1999-05-12 | Corixa Corporation | Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer |
| EP1005546A2 (en) * | 1997-02-25 | 2000-06-07 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
| US20030185830A1 (en) * | 1997-02-25 | 2003-10-02 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| ES2324503T3 (es) * | 1997-04-10 | 2009-08-07 | Stichting Katholieke Universiteit University Medical Centre Nijmegen | Pca3, genes pca3 y metodos de uso. |
| US6187799B1 (en) * | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
| US6828429B1 (en) * | 1999-03-26 | 2004-12-07 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Prostate-specific gene, PCGEM1, and the methods of using PCGEM1 to detect, treat, and prevent prostate cancer |
| CA2423154A1 (en) * | 2000-09-21 | 2002-03-28 | David Kenneth Dean | Imidazole derivatives as raf kinase inhibitors |
| US6897024B2 (en) * | 2001-05-31 | 2005-05-24 | Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen | Nucleic acid molecules comprising the promoter for PCA3, and uses thereof |
| US7229774B2 (en) * | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
| US7217807B2 (en) * | 2002-11-26 | 2007-05-15 | Rosetta Genomics Ltd | Bioinformatically detectable group of novel HIV regulatory genes and uses thereof |
| KR20060031809A (ko) * | 2003-06-09 | 2006-04-13 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 암 치료 및 진단용 조성물 및 방법 |
| WO2005026687A2 (en) * | 2003-09-05 | 2005-03-24 | Thomas Jefferson University | Diagnosis and monitoring of hepatocellular carcinoma |
| CN101018874A (zh) * | 2004-08-13 | 2007-08-15 | 千年药品公司 | 用于鉴定、评估、预防和治疗前列腺癌的基因、组合物、试剂盒和方法 |
| US20060275794A1 (en) * | 2005-03-07 | 2006-12-07 | Invitrogen Corporation | Collections of matched biological reagents and methods for identifying matched reagents |
| US7718369B2 (en) * | 2005-09-12 | 2010-05-18 | The Regents Of The University Of Michigan | Recurrent gene fusions in prostate cancer |
| EP2074225B1 (en) * | 2006-10-10 | 2014-12-03 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Prostate cancer-specific alterations in erg gene expression and detection and treatment methods based on those alterations |
| WO2009044899A1 (ja) * | 2007-10-03 | 2009-04-09 | Kyowa Hakko Kirin Co., Ltd. | 細胞の増殖を制御する核酸 |
-
2007
- 2007-11-08 AU AU2007317306A patent/AU2007317306B2/en not_active Ceased
- 2007-11-08 WO PCT/US2007/084090 patent/WO2008058239A2/en not_active Ceased
- 2007-11-08 EP EP20070864115 patent/EP2079851B1/en active Active
- 2007-11-08 JP JP2009536481A patent/JP2010508855A/ja active Pending
- 2007-11-08 CN CN2007800495248A patent/CN101652484B/zh not_active Expired - Fee Related
- 2007-11-08 CA CA 2668961 patent/CA2668961A1/en not_active Abandoned
- 2007-11-08 US US12/513,637 patent/US20100129804A1/en not_active Abandoned
- 2007-11-08 CN CN2013100513934A patent/CN103233063A/zh active Pending
-
2009
- 2009-05-03 IL IL198526A patent/IL198526A/en not_active IP Right Cessation
-
2011
- 2011-09-25 IL IL21537311A patent/IL215373A/en not_active IP Right Cessation
-
2013
- 2013-10-21 JP JP2013218134A patent/JP5850898B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010508855A5 (enExample) | ||
| EP2890815B1 (en) | Methods for diagnosis and treatment of cancer | |
| CN103642810B (zh) | 一种核酸适配体及其筛选方法、在检测前列腺癌细胞株中的应用 | |
| CN103146688B (zh) | 长链非编码rna作为疾病诊断血液分子标志物的应用 | |
| JP6534930B2 (ja) | Ｎｔｒｋ３融合体の検出法 | |
| Song et al. | Microarray analysis of normal cervix, carcinoma in situ, and invasive cervical cancer: identification of candidate genes in pathogenesis of invasion in cervical cancer | |
| JP2017108751A5 (enExample) | ||
| CA2262403A1 (en) | Biomarkers and targets for diagnosis, prognosis and management of prostate disease | |
| JP2007537197A5 (enExample) | ||
| JP2008509673A5 (enExample) | ||
| CA2362527A1 (en) | A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer | |
| KR101698654B1 (ko) | En2에 특이적으로 결합하는 dna 압타머 및 이의 용도 | |
| JP2008067704A (ja) | 良性および悪性の前立腺組織におけるｐｃａ３メッセンジャーｒｎａ種 | |
| JP2009539370A5 (enExample) | ||
| WO2011093606A2 (ko) | Pna 기반의 실시간 pcr 클램핑을 이용한 braf 돌연변이 검출 방법 및 키트 | |
| KR101513766B1 (ko) | 알파태아단백질에 특이적으로 결합하는 ｄｎａ 앱타머 및 이의 용도 | |
| CN106460060A (zh) | Hnf4g‑rspo2融合基因及其在癌症治疗中的用途 | |
| KR101670135B1 (ko) | 리포칼린 2 단백질에 특이적으로 결합하는 dna 앱타머 및 이의 용도 | |
| CN111944821A (zh) | 一种结肠癌核酸适体的组织样本快速筛选及其在检测制剂中的应用 | |
| US10895574B2 (en) | Left-right gene expression signature for triple negative breast cancer | |
| KR20170056126A (ko) | 스핑크１ 단백질에 특이적으로 결합하는 ｄｎａ 앱타머 및 이의 용도 | |
| KR20170124683A (ko) | 담도암 진단용 신규 바이오마커로서의 융합 유전자 및 융합 단백질 | |
| US20070264651A1 (en) | Methods, compositions, and kits for the detection and monitoring of kidney cancer | |
| US20080108070A1 (en) | Methods, compositions, and kits for the detection and monitoring of colon cancer | |
| KR20120094173A (ko) | 유방암 줄기세포 특이적 마커인 ｃｄ４４ 단백질 표적용 펩타이드 및 이의 이용 |